Literature DB >> 21224254

Disruption of adaptive energy metabolism and elevated ribosomal p-S6K1 levels contribute to INCL pathogenesis: partial rescue by resveratrol.

Hui Wei1, Zhongjian Zhang, Arjun Saha, Shiyong Peng, Goutam Chandra, Zenaide Quezado, Anil B Mukherjee.   

Abstract

The infantile neuronal ceroid lipofuscinosis (INCL) is a devastating neurodegenerative lysosomal storage disease. Despite our knowledge that palmitoyl-protein thioesterase-1 (PPT1)-deficiency causes INCL, the molecular mechanism(s) of neurodegeneration and the drastically reduced lifespan of these patients remain poorly understood. Consequently, an effective treatment for this disease is currently unavailable. We previously reported that oxidative stress-mediated abnormality in mitochondria activates caspases-9 pathway of apoptosis in INCL fibroblasts and in neurons of Ppt1-knockout (Ppt1-KO) mice, which mimic INCL. Since mitochondria play critical roles in maintaining cellular energy homeostasis, we hypothesized that oxidative stress-mediated disruption of energy metabolism and homeostasis may contribute to INCL pathogenesis. We report here that, in cultured INCL fibroblasts and in the brain tissues of Ppt1-KO mice, the NAD(+)/NADH ratio, the levels of phosphorylated-AMPK (p-AMPK), peroxisome proliferator-activated receptor-γ (PPARγ) coactivator-1α (PGC-1α) and Silent Information Regulator T1 (SIRT1) are markedly down-regulated. This suggested an abnormality in AMPK/SIRT1/PGC-1α signaling pathway of energy metabolism. Moreover, we found that, in INCL fibroblasts and in the Ppt1-KO mice, phosphorylated-S6K-1 (p-S6K1) levels, which inversely correlate with lifespan, are markedly elevated. Most importantly, resveratrol (RSV), an antioxidant polyphenol, elevated the NAD(+)/NADH ratio, levels of ATP, p-AMPK, PGC-1α and SIRT1 while decreasing the level of p-S6K1 in both INCL fibroblasts and in Ppt1-KO mice, which showed a modest increase in lifespan. Our results show that disruption of adaptive energy metabolism and increased levels of p-S6K1 are contributing factors in INCL pathogenesis and provide the proof of principle that small molecules such as RSV, which alleviate these abnormalities, may have therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21224254      PMCID: PMC3043662          DOI: 10.1093/hmg/ddq555

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  46 in total

Review 1.  Brain-directed gene therapy for lysosomal storage disease: going well beyond the blood- brain barrier.

Authors:  William S Sly; Carole Vogler
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-30       Impact factor: 11.205

2.  Increased wheel-running activity in the genetically skeletal muscle fast-twitch fiber-dominant rats.

Authors:  Masataka Suwa; Hiroshi Nakano; Yasuki Higaki; Tomohiro Nakamura; Shigeru Katsuta; Shuzo Kumagai
Journal:  J Appl Physiol (1985)       Date:  2002-09-06

Review 3.  Neuronal degeneration and mitochondrial dysfunction.

Authors:  Eric A Schon; Giovanni Manfredi
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

4.  Blood to brain to the rescue.

Authors:  Richard L Proia; Yun-Ping Wu
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

5.  Disruption of PPT1 or PPT2 causes neuronal ceroid lipofuscinosis in knockout mice.

Authors:  P Gupta; A A Soyombo; A Atashband; K E Wisniewski; J M Shelton; J A Richardson; R E Hammer; S L Hofmann
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

6.  Activation of AMPK is essential for AICAR-induced glucose uptake by skeletal muscle but not adipocytes.

Authors:  Hideyuki Sakoda; Takehide Ogihara; Motonobu Anai; Midori Fujishiro; Hiraku Ono; Yukiko Onishi; Hideki Katagiri; Miho Abe; Yasushi Fukushima; Nobuhiro Shojima; Kouichi Inukai; Masatoshi Kikuchi; Yoshitomo Oka; Tomoichiro Asano
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-06       Impact factor: 4.310

Review 7.  The AMP-activated protein kinase cascade--a unifying system for energy control.

Authors:  David Carling
Journal:  Trends Biochem Sci       Date:  2004-01       Impact factor: 13.807

8.  AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation.

Authors:  Haihong Zong; Jian Ming Ren; Lawrence H Young; Marc Pypaert; James Mu; Morris J Birnbaum; Gerald I Shulman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-20       Impact factor: 11.205

Review 9.  Current state of clinical and morphological features in human NCL.

Authors:  Hans H Goebel; Krystyna E Wisniewski
Journal:  Brain Pathol       Date:  2004-01       Impact factor: 6.508

10.  Production of lysophosphatidylcholine by cPLA2 in the brain of mice lacking PPT1 is a signal for phagocyte infiltration.

Authors:  Zhongjian Zhang; Yi-Ching Lee; Sung-Jo Kim; Moonsuk S Choi; Pei-Chih Tsai; Arjun Saha; Hui Wei; Yan Xu; Yi-Jin Xiao; Peng Zhang; Alison Heffer; Anil B Mukherjee
Journal:  Hum Mol Genet       Date:  2007-03-06       Impact factor: 6.150

View more
  21 in total

1.  Combination small molecule PPT1 mimetic and CNS-directed gene therapy as a treatment for infantile neuronal ceroid lipofuscinosis.

Authors:  Marie S Roberts; Shannon L Macauley; Andrew M Wong; Denis Yilmas; Sarah Hohm; Jonathan D Cooper; Mark S Sands
Journal:  J Inherit Metab Dis       Date:  2012-02-07       Impact factor: 4.982

2.  Treatment of the Ppt1(-/-) mouse model of infantile neuronal ceroid lipofuscinosis with the N-methyl-D-aspartate (NMDA) receptor antagonist memantine.

Authors:  Rozzy Finn; Attila D Kovács; David A Pearce
Journal:  J Child Neurol       Date:  2013-09       Impact factor: 1.987

3.  Considerations for the treatment of infantile neuronal ceroid lipofuscinosis (infantile Batten disease).

Authors:  Mark S Sands
Journal:  J Child Neurol       Date:  2013-09       Impact factor: 1.987

Review 4.  Linking mitochondrial dysfunction to neurodegeneration in lysosomal storage diseases.

Authors:  Afshin Saffari; Stefan Kölker; Georg F Hoffmann; Darius Ebrahimi-Fakhari
Journal:  J Inherit Metab Dis       Date:  2017-05-05       Impact factor: 4.982

5.  Synergistic effects of central nervous system-directed gene therapy and bone marrow transplantation in the murine model of infantile neuronal ceroid lipofuscinosis.

Authors:  Shannon L Macauley; Marie S Roberts; Andrew M Wong; Francesca McSloy; Adarsh S Reddy; Jonathan D Cooper; Mark S Sands
Journal:  Ann Neurol       Date:  2012-02-24       Impact factor: 10.422

6.  Stop codon read-through with PTC124 induces palmitoyl-protein thioesterase-1 activity, reduces thioester load and suppresses apoptosis in cultured cells from INCL patients.

Authors:  Chinmoy Sarkar; Zhongjian Zhang; Anil B Mukherjee
Journal:  Mol Genet Metab       Date:  2011-06-13       Impact factor: 4.797

Review 7.  Pathogenesis and therapies for infantile neuronal ceroid lipofuscinosis (infantile CLN1 disease).

Authors:  Jacqueline A Hawkins-Salsbury; Jonathan D Cooper; Mark S Sands
Journal:  Biochim Biophys Acta       Date:  2013-06-06

8.  Aβ25-35 Suppresses Mitochondrial Biogenesis in Primary Hippocampal Neurons.

Authors:  Weiguo Dong; Feng Wang; Wanqing Guo; Xuehua Zheng; Yue Chen; Wenguang Zhang; Hong Shi
Journal:  Cell Mol Neurobiol       Date:  2015-06-09       Impact factor: 5.046

9.  The blood-brain barrier is disrupted in a mouse model of infantile neuronal ceroid lipofuscinosis: amelioration by resveratrol.

Authors:  Arjun Saha; Chinmoy Sarkar; Satya P Singh; Zhongjian Zhang; Jeeva Munasinghe; Shiyong Peng; Goutam Chandra; Eryan Kong; Anil B Mukherjee
Journal:  Hum Mol Genet       Date:  2012-02-13       Impact factor: 6.150

10.  Proteomic Profiling in the Brain of CLN1 Disease Model Reveals Affected Functional Modules.

Authors:  Saara Tikka; Evanthia Monogioudi; Athanasios Gotsopoulos; Rabah Soliymani; Francesco Pezzini; Enzo Scifo; Kristiina Uusi-Rauva; Jaana Tyynelä; Marc Baumann; Anu Jalanko; Alessandro Simonati; Maciej Lalowski
Journal:  Neuromolecular Med       Date:  2015-12-26       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.